Prognostic significance of serum β2-microglobulin levels in patients with peripheral T-cell lymphoma not otherwise specified

Abstract

We aimed to investigate the prognostic value of serum β2-microglobulin in patients with peripheral T-cell lymphoma-not otherwise specified (PTCL-NOS). A cohort study of PTCL-NOS patients (n = 147) was conducted. An elevated serum β2-microglobulin level was associated with the presence of previously identified predictors of a poor prognosis for PTCL-NOS. Patients with an elevated serum β2-microglobulin level exhibited a significantly worse progression-free survival (PFS) and overall survival (OS). Multivariate analyses revealed that an elevated serum β2-microglobulin level was independently associated with a shorter PFS and OS. A new prognostic index incorporating the serum β2-microglobulin level allowed for the stratification of patients into three distinct risk subgroups. The index was validated to stratify patients with distinct survival outcomes in an independent cohort of PTCL-NOS (n = 89). In conclusion, serum β2-microglobulin level is an independent prognostic factor in patients with PTCL-NOS. Our β2-microglobulin-based prognostic index for PTCL-NOS deserves further investigation and validation.

Keywords:

• Peripheral T-cell lymphoma-not otherwise specified
• β2-microglobulin
• prognostic factor
• risk stratification
• prognostic index

Disclosure statement

There are no relevant conflicts of interest to declare.

Author contributions

HDK and CS contributed to the conceptual design of the study. HDK, HW, BSS, CSP, JH, JSR, SWL, SEY, SJK, YHK, WSK and CS were involved in data acquisition. HDK, HW, BSS, CSP, JH, JSR, SWL, SEY, SJK, YHK, WSK, and CS were involved in data analysis and interpretation. HDK and CS were involved in writing and editing the manuscript. HDK, HW, BSS, CSP, JH, JSR, SWL, SEY, SJK, YHK, WSG and CS reviewed the manuscript. This study was supervised by CS.